Literature DB >> 15994075

The prevalence of PIK3CA mutations in gastric and colon cancer.

Sérgia Velho1, Carla Oliveira, Ana Ferreira, António Carlos Ferreira, Gianpaolo Suriano, Simó Schwartz, Alex Duval, Fátima Carneiro, José Carlos Machado, Richard Hamelin, Raquel Seruca.   

Abstract

A wide variety of tumours show PIK3CA mutations leading to increased phosphatidylinositol-3 kinase (PI3K) activity. We have determined the frequency of PIK3CA mutations in exons 9 and 20 that has previously been reported as mutational hotspot regions in distinct tumour models. One hundred and fifty gastrointestinal carcinomas (47 gastric and 103 colorectal) that were characterised for MSI status (76 MSI and 74 MSS) by PCR-SSCP sequencing were evaluated. We also analysed the association between PIK3CA mutations and KRAS or BRAF mutations. PIK3CA mutations in exons 9 and 20 were present in 13.6% and 10.6% of colorectal and gastric carcinomas, respectively. No differences in frequency and type of PIK3CA mutations were found between MSI and MSS colorectal carcinomas. All gastric carcinomas with PIK3CA mutations were MSI. The number of cases harbouring concomitant PIK3CA and KRAS or BRAF mutations was higher in colorectal than in gastric carcinomas (P = 0.016). In colorectal carcinoma, PIK3CA mutations occur preferentially together with activating KRAS-BRAF mutations (MSI and MSS) while in gastric carcinomas PIK3CA mutations tend to occur as isolated events (MSI).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994075     DOI: 10.1016/j.ejca.2005.04.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  136 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.

Authors:  Z B Mei; C Y Duan; C B Li; L Cui; S Ogino
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

3.  KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity.

Authors:  Pedro Queirós; Hugo Pinheiro; Joana Carvalho; Patrícia Oliveira; Irene Gullo; Fátima Carneiro; Gabriela M Almeida; Carla Oliveira
Journal:  Virchows Arch       Date:  2015-08-29       Impact factor: 4.064

4.  Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.

Authors:  Pedro R Cutillas; Asim Khwaja; Mariona Graupera; Wayne Pearce; Severine Gharbi; Mike Waterfield; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

5.  Rare cancer-specific mutations in PIK3CA show gain of function.

Authors:  Marco Gymnopoulos; Marc-André Elsliger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-21       Impact factor: 11.205

6.  Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Authors:  Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

Review 7.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

8.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

Review 9.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

Review 10.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.